Merit Medical Systems, Inc.

What they do

Merit Medical designs, develops, manufactures, and sells medical devices used in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two segments: cardiovascular, which includes peripheral intervention, cardiac intervention, custom procedural solutions, and OEM; and endoscopy, which sells gastroenterology and pulmonology devices. Products include vascular access devices, embolotherapy products, cardiac rhythm management devices, and esophageal and airway stents.

Revenue drivers

• Peripheral Intervention (Cardiovascular) — Largest product category; 2025 sales of $579.8 million, up 8.8% year-over-year, driven by access, angiography, drainage, delivery systems, embolotherapy, and oncology products.
• Cardiac Intervention (Cardiovascular) — 2025 sales of $448.9 million, up 21.7% year-over-year, reflecting strong demand for cardiac therapy devices.
• OEM (Cardiovascular) — 2025 sales of $205.0 million, up 2.5%; includes original equipment manufacturer products and, since 2025, spine devices (recast for comparability).
• Endoscopy — Smallest segment but fastest-growing; 2025 sales of $72.9 million, up 33.0% year-over-year, driven by devices for treating strictures in the esophagus, tracheobronchial tree, and biliary system.

Recent performance

For Q2 2026, Merit reported revenue of $418.8 million, up 10% year-over-year, with constant currency organic growth of 9%. Gross margin expanded to 51.4% from 48.2% in the prior-year period, and net income rose to $38.8 million ($0.65 per share) from $32.6 million ($0.54). For the six months ended June 30, 2026, revenue was $800.7 million, up 9%, and net income was $79.8 million ($1.33 per share). Cash flow from operations was $110.0 million year-to-date, down 11%.

Strategy

Merit is executing its 'Continued Growth Initiatives' program, with multi-year financial targets through December 31, 2026, focusing on revenue growth, profitability, and cash flow. Management is developing a longer-term strategic plan to identify opportunities for sustainable growth and enhanced profitability. Recent acquisitions include Biolife (hemostatic devices, May 2025), the C2 CryoBalloon (November 2025), and View Point (April 2026, tissue markers). The company also reorganized sales teams and product categories, including moving spine devices into the OEM category, to better align with foundational and therapeutic product platforms.

Risks

• Supply chain disruptions — Dependence on third-party vendors for raw materials, components, and sterilization services could cause product shortages or price increases, especially given limited sources for petroleum-based materials.
• Tariff and trade uncertainty — Following the Supreme Court ruling on IEEPA tariffs, Merit received only a partial refund ($6.9 million in Q2 2026) and faces uncertainty about recovering remaining amounts, including for products where it is not the importer of record.
• Integration of acquisitions — Recent acquisitions (Biolife, C2 CryoBalloon, View Point) may not achieve expected synergies or financial performance, and integration could consume management time and resources.
• Foreign exchange exposure — A significant portion of sales is international; adverse currency fluctuations could negatively impact reported revenue and profitability, though hedging partially mitigates this risk.

Outlook

Management increased full-year 2026 revenue and non-GAAP EPS guidance due to stronger-than-expected first-half results. They expect continued constant currency growth, improving profitability, and solid cash flow generation. The company remains focused on achieving the Continued Growth Initiative targets for 2026 and is developing a longer-term strategic plan.